2023
Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li F, Ferrucci L, Puklin L, Cao A, Nguyen T, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Tanasijevic A, Ligibel J, Irwin M. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal Of Clinical Oncology 2023, 41: 5285-5295. PMID: 37656930, PMCID: PMC10691793, DOI: 10.1200/jco.23.00871.Peer-Reviewed Original ResearchConceptsRelative dose intensityPathologic complete responseProportion of patientsBreast cancerNeoadjuvant chemotherapyChemotherapy completionComplete responseNutrition interventionsHigher pathologic complete responseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerChemotherapy dose adjustmentsHome-based exerciseGrowth factor receptor 2Breast cancer outcomesEffects of exerciseFactor receptor 2Electronic medical recordsChi-square testUsual careDose intensityExercise interventionDose adjustmentRandomized trials
2022
Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.
Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.Peer-Reviewed Original ResearchRelative dose intensityHigh relative dose intensityBreast cancerDose-response effectPhysical activityPA interventionsNeoadjuvant chemotherapyChemotherapy completionDiet qualityStage I breast cancerEndocrine therapy adherenceTrial of dietDifferent chemotherapy regimensI breast cancerBody mass indexPatient-reported outcomesHealthy Eating IndexBetter diet qualityHigh physical activityMore physical activityElectronic medical recordsChi-square testUC participantsChemotherapy regimensSecondary endpoints
2017
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.Peer-Reviewed Original ResearchPathologic complete response rateHER2-positive breast cancerDual HER2 blockadeComplete response ratePCR rateEstrogen receptorHER2 blockadeBreast cancerStage IResponse rateGrade 3/4 adverse eventsSymptomatic congestive heart failureClinical stage ICompletion of chemotherapyPhase II studyTaxane-based chemotherapyCongestive heart failureEfficacy of anthracyclinesPositive breast cancerNormal cardiac functionEntire treatment durationER- cancersER cohortNeoadjuvant pertuzumabWeekly paclitaxel
2016
Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.
Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.Peer-Reviewed Original Research
2015
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.Peer-Reviewed Original ResearchMutation-based treatment recommendations from next generation sequencing data: A comparison of web tools.
Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Gershkovich P, Hatzis C, Pusztai L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. DOI: 10.1200/jco.2015.33.15_suppl.e12564.Peer-Reviewed Original Research
2014
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.
Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.Peer-Reviewed Original ResearchCardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.
Park E, Abu-Khalaf M, Hatzis C, LaSala J, Silber A, Hofstatter E, Sanft T, Russell R. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. Journal Of Clinical Oncology 2014, 32: e11501-e11501. DOI: 10.1200/jco.2014.32.15_suppl.e11501.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply